Cargando…

Is there any Benefit with Pantoprazole Treatment in Infantile Hypertrophic Pyloric Stenosis?

CONTEXT: Previous studies demonstrated faster correction of metabolic derangement associated with hypertrophic pyloric stenosis with pre-operative intravenous (IV) histamine-2 receptor antagonists. AIMS: We investigated if similar outcomes are achieved with IV pantoprazole, a proton-pump inhibitor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Fourie, Natasha, Arnold, Marion, Banieghbal, Behrouz, Marchant, Samantha Lynn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759415/
https://www.ncbi.nlm.nih.gov/pubmed/34916353
http://dx.doi.org/10.4103/ajps.AJPS_9_21
_version_ 1784633103668477952
author Fourie, Natasha
Arnold, Marion
Banieghbal, Behrouz
Marchant, Samantha Lynn
author_facet Fourie, Natasha
Arnold, Marion
Banieghbal, Behrouz
Marchant, Samantha Lynn
author_sort Fourie, Natasha
collection PubMed
description CONTEXT: Previous studies demonstrated faster correction of metabolic derangement associated with hypertrophic pyloric stenosis with pre-operative intravenous (IV) histamine-2 receptor antagonists. AIMS: We investigated if similar outcomes are achieved with IV pantoprazole, a proton-pump inhibitor (PPI), including the subgroup of delayed presenters in the South African setting. SETTINGS AND DESIGN: A 5-year retrospective record review (January 2014–December 2018) compared the rate of metabolic correction in patients with hypertrophic pyloric stenosis at two tertiary centres. SUBJECTS AND METHODS: One centre routinely administers IV pantoprazole (1 mg/kg daily) preoperatively (PPI group) and the other does not (non-PPI group). Fluid administration, chloride supplementation and post-operative emesis were evaluated. STATISTICAL ANALYSIS: Spearman's rank correlation coefficient was used to calculate statistical significance for discrete dependent variables. Continuous variables were compared between the groups using the Student t-test. Fisher's exact contingency tables were used to classify categorical data and to assess the significance of outcome between two treatment options. P < 0.05 was considered statistically significant. RESULTS: Forty-two patients received IV pantoprazole and 24 did not. The mean time of metabolic correction was 8 h shorter in the PPI group (P = 0.067). Total pre-operative chloride administration correlated to the rate of metabolic correction in both cohorts (P < 0.0001). Profound hypochloraemia (chloride <85 mmol/l) was corrected 23 h faster in the PPI group (P < 0.004). Post-operative emesis was noted: 0.45 episodes/patient in the PPI group and 0.75 episodes/patient in the non-PPI group (P = 0.01). CONCLUSIONS: Pre-operative IV pantoprazole administration showed a faster correction of metabolic derangements, and in profound hypochloraemia, the correction occurred substantially faster in the PPI group. Post-operative emesis was significantly less frequent in the PPI group.
format Online
Article
Text
id pubmed-8759415
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-87594152022-01-21 Is there any Benefit with Pantoprazole Treatment in Infantile Hypertrophic Pyloric Stenosis? Fourie, Natasha Arnold, Marion Banieghbal, Behrouz Marchant, Samantha Lynn Afr J Paediatr Surg Original Article CONTEXT: Previous studies demonstrated faster correction of metabolic derangement associated with hypertrophic pyloric stenosis with pre-operative intravenous (IV) histamine-2 receptor antagonists. AIMS: We investigated if similar outcomes are achieved with IV pantoprazole, a proton-pump inhibitor (PPI), including the subgroup of delayed presenters in the South African setting. SETTINGS AND DESIGN: A 5-year retrospective record review (January 2014–December 2018) compared the rate of metabolic correction in patients with hypertrophic pyloric stenosis at two tertiary centres. SUBJECTS AND METHODS: One centre routinely administers IV pantoprazole (1 mg/kg daily) preoperatively (PPI group) and the other does not (non-PPI group). Fluid administration, chloride supplementation and post-operative emesis were evaluated. STATISTICAL ANALYSIS: Spearman's rank correlation coefficient was used to calculate statistical significance for discrete dependent variables. Continuous variables were compared between the groups using the Student t-test. Fisher's exact contingency tables were used to classify categorical data and to assess the significance of outcome between two treatment options. P < 0.05 was considered statistically significant. RESULTS: Forty-two patients received IV pantoprazole and 24 did not. The mean time of metabolic correction was 8 h shorter in the PPI group (P = 0.067). Total pre-operative chloride administration correlated to the rate of metabolic correction in both cohorts (P < 0.0001). Profound hypochloraemia (chloride <85 mmol/l) was corrected 23 h faster in the PPI group (P < 0.004). Post-operative emesis was noted: 0.45 episodes/patient in the PPI group and 0.75 episodes/patient in the non-PPI group (P = 0.01). CONCLUSIONS: Pre-operative IV pantoprazole administration showed a faster correction of metabolic derangements, and in profound hypochloraemia, the correction occurred substantially faster in the PPI group. Post-operative emesis was significantly less frequent in the PPI group. Wolters Kluwer - Medknow 2022 2021-12-14 /pmc/articles/PMC8759415/ /pubmed/34916353 http://dx.doi.org/10.4103/ajps.AJPS_9_21 Text en Copyright: © 2022 African Journal of Paediatric Surgery https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Fourie, Natasha
Arnold, Marion
Banieghbal, Behrouz
Marchant, Samantha Lynn
Is there any Benefit with Pantoprazole Treatment in Infantile Hypertrophic Pyloric Stenosis?
title Is there any Benefit with Pantoprazole Treatment in Infantile Hypertrophic Pyloric Stenosis?
title_full Is there any Benefit with Pantoprazole Treatment in Infantile Hypertrophic Pyloric Stenosis?
title_fullStr Is there any Benefit with Pantoprazole Treatment in Infantile Hypertrophic Pyloric Stenosis?
title_full_unstemmed Is there any Benefit with Pantoprazole Treatment in Infantile Hypertrophic Pyloric Stenosis?
title_short Is there any Benefit with Pantoprazole Treatment in Infantile Hypertrophic Pyloric Stenosis?
title_sort is there any benefit with pantoprazole treatment in infantile hypertrophic pyloric stenosis?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759415/
https://www.ncbi.nlm.nih.gov/pubmed/34916353
http://dx.doi.org/10.4103/ajps.AJPS_9_21
work_keys_str_mv AT fourienatasha isthereanybenefitwithpantoprazoletreatmentininfantilehypertrophicpyloricstenosis
AT arnoldmarion isthereanybenefitwithpantoprazoletreatmentininfantilehypertrophicpyloricstenosis
AT banieghbalbehrouz isthereanybenefitwithpantoprazoletreatmentininfantilehypertrophicpyloricstenosis
AT marchantsamanthalynn isthereanybenefitwithpantoprazoletreatmentininfantilehypertrophicpyloricstenosis